Effect of liraglutide on anthropometric measurements, sagittal abdominal diameter and adiponectin levels in people with type 2 diabetes treated with multiple daily insulin injections: evaluations from a randomized trial (MDI-liraglutide study 5)

被引:13
作者
Ahmadi, S. S. [1 ]
Filipsson, K. [2 ]
Dimenaes, H. [3 ]
Isaksson, S. S. [1 ,11 ]
Imberg, H. [4 ,5 ,14 ]
Sjoeberg, S. [6 ]
Ahren, B. [2 ,7 ]
Dahlqvist, S. [11 ]
Gustafsson, T. [13 ]
Tuomilehto, J. [8 ,9 ,10 ]
Hirsch, I. B. [12 ]
Lind, M. [1 ,11 ]
机构
[1] Univ Gothenburg, Dept Mol & Clin Med, Gothenburg, Sweden
[2] Lund Univ, Dept Clin Sci Lund, Lund, Sweden
[3] South Alvsborg Hosp, Dept Med, Boras, Sweden
[4] Chalmers Univ Technol, Dept Math Sci, Gothenburg, Sweden
[5] Univ Gothenburg, Gothenburg, Sweden
[6] Karolinska Univ Hosp Huddinge, Dept Med, Karolinska Inst, Stockholm, Sweden
[7] Lund Univ, Lund, Sweden
[8] Danube Univ, Ctr Vasc Prevent, Krems, Austria
[9] Natl Inst Hlth & Welf, Dept Chron Dis Prevent, Helsinki, Finland
[10] King Abdulaziz Univ, Diabet Res Grp, Jeddah, Saudi Arabia
[11] NU Hosp Grp, Dept Med, Uddevalla, Sweden
[12] Univ Washington, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA
[13] Karolinska Univ Hosp, Dept Clin Chem, Stockholm, Sweden
[14] Stat Konsultgrp, Gothenburg, Sweden
关键词
Adiponectin; anthropometric measurements; liraglutide; predictive variable; EUROPEAN ASSOCIATION; POSITION STATEMENT; RECEPTOR AGONISTS; PEPTIDE-1; ANALOG; MANAGEMENT; APPETITE; HYPERGLYCEMIA; WEIGHT;
D O I
10.1002/osp4.324
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim Use of the glucagon-like peptide 1 receptor agonist liraglutide has been shown to reduce weight. Different types of anthropometric measurements can be used to measure adiposity. This study evaluated the effect of liraglutide on sagittal abdominal diameter, waist circumference, waist-to-hip ratio and adiponectin levels in people with type 2 diabetes (T2D) treated with multiple daily insulin injections (MDI). Materials and methods In the multicentre, double-blind, placebo-controlled MDI-liraglutide trial, 124 individuals with T2D treated with MDI were randomized to either liraglutide or placebo. Basal values of weight, waist circumference, waist-to-hip ratio, sagittal abdominal diameter and adiponectin were compared with measurements at 12 and 24 weeks after randomization. Results Baseline-adjusted mean weight loss was 3.8 +/- 2.9 kg greater in liraglutide than placebo-treated individuals (p < 0.0001). Waist circumference was reduced by 2.9 +/- 4.3 cm and 0.2 +/- 3.6 cm in the liraglutide and placebo groups, respectively, after 24 weeks (baseline-adjusted mean difference: 2.6 +/- 4.0 cm, p = 0.0005). Corresponding reductions in sagittal abdominal diameter were 1.1 +/- 1.7 cm and 0.0 +/- 1.8 cm (baseline-adjusted mean difference: 1.1 +/- 1.7 cm, p = 0.0008). Hip circumference was reduced in patients randomized to liraglutide (baseline-adjusted mean difference between treatment groups: 2.8 +/- 3.8 cm, p = 0.0001), but there was no significant difference between the groups in either waist-to-hip ratio (baseline-adjusted mean difference: 0.0 +/- 0.04 cm, p = 0.51) or adiponectin levels (baseline-adjusted mean difference: 0.8 +/- 3.3 mg L-1, p = 0.17). Lower HbA1c and mean glucose levels measured by masked continuous glucose monitoring at baseline were associated with greater effects of liraglutide on reductions in waist circumference and sagittal abdominal diameter. Conclusions In patients with T2D, adding liraglutide to MDI may reduce abdominal and hip obesity to a similar extent, suggesting an effect on both visceral and subcutaneous fat. Liraglutide had greater effects on reducing abdominal obesity in patients with less pronounced long-term hyperglycaemia but did not affect adiponectin levels.
引用
收藏
页码:130 / 140
页数:11
相关论文
共 29 条
[1]  
[Anonymous], GLYCAEMIC CONTROL EV
[2]  
Bjorntorp P, 1997, NUTRITION, V13, P795, DOI 10.1016/s0899-9007(97)00191-3
[3]   Variables associated with HbA1c and weight reductions when adding liraglutide to multiple daily insulin injections in persons with type 2 diabetes (MDI Liraglutide trial 3) [J].
Dahlqvist, Sofia ;
Ahlen, Elsa ;
Filipsson, Karin ;
Gustafsson, Thomas ;
Hirsch, Irl B. ;
Tuomilehto, Jaakko ;
Imberg, Henrik ;
Ahren, Bo ;
Attvall, Stig ;
Lind, Marcus .
BMJ OPEN DIABETES RESEARCH & CARE, 2018, 6 (01)
[4]  
Davies MJ, 2018, DIABETES CARE, V41, P2669, DOI [10.2337/dci18-0033, 10.1007/s00125-018-4729-5]
[5]   Antiobesity efficacy of GLP-1 receptor agonist liraglutide is associated with peripheral tissue-specific modulation of lipid metabolic regulators [J].
Decara, Juan ;
Arrabal, Sergio ;
Beiroa, Daniel ;
Rivera, Patricia ;
Vargas, Antonio ;
Serrano, Antonia ;
Javier Pavon, Francisco ;
Ballesteros, Joan ;
Dieguez, Carlos ;
Nogueiras, Ruben ;
Rodriguez de Fonseca, Fernando ;
Suarez, Juan .
BIOFACTORS, 2016, 42 (06) :600-611
[6]  
Esfahani M, 2015, IRAN J BASIC MED SCI, V18, P430
[7]  
Haluzik Martin, 2005, Curr Opin Investig Drugs, V6, P988
[8]   Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes [J].
Horowitz, Michael ;
Flint, Anne ;
Jones, Karen L. ;
Hindsberger, Charlotte ;
Rasmussen, Mads F. ;
Kapitza, Christoph ;
Doran, Selena ;
Jax, Thomas ;
Zdravkovic, Milan ;
Chapman, Ian M. .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2012, 97 (02) :258-266
[9]   Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes [J].
Inoue, Kana ;
Maeda, Norikazu ;
Kashine, Susumu ;
Fujishima, Yuya ;
Kozawa, Junji ;
Hiuge-Shimizu, Aki ;
Okita, Kohei ;
Imagawa, Akihisa ;
Funahashi, Tohru ;
Shimomura, Iichiro .
CARDIOVASCULAR DIABETOLOGY, 2011, 10
[10]  
International Diabetes Federation, 2017, IDF Diabetes Atlas, V8th ed.